YOR034C-A Antibody

What is YOR034C-A and why is it significant for Saccharomyces cerevisiae research?

YOR034C-A refers to a specific gene/protein in Saccharomyces cerevisiae (Baker's yeast), identified by the systematic name YOR034C-A and represented in the UniProt database as Q3E735 . This protein is studied within the broader context of yeast molecular biology, which serves as a powerful eukaryotic model organism for high-throughput genetic analyses. Yeast models have consistently provided insights that further our understanding of cell biology processes conserved in humans . YOR034C-A antibodies are critical reagents that enable researchers to detect, quantify, localize, and study the expression patterns of this protein in experimental settings.

What standard applications are recommended for YOR034C-A antibodies?

The YOR034C-A antibody (CSB-PA662958XA01SVG) has been tested and validated for specific applications including ELISA and Western Blot (WB) . These applications enable researchers to:

• Detect and quantify YOR034C-A protein expression levels in yeast samples

• Investigate protein presence in different cellular fractions

• Examine potential post-translational modifications

• Study protein-protein interactions through co-immunoprecipitation protocols

When designing experiments using this antibody, researchers should ensure proper identification of the antigen and incorporate appropriate controls to validate specificity in their particular experimental system .

What are the optimal storage and handling conditions for YOR034C-A antibodies?

For maximum stability and performance, YOR034C-A antibodies should be stored at -20°C or -80°C upon receipt . Repeated freeze-thaw cycles should be avoided as they can compromise antibody integrity and performance. The antibody solution contains 50% glycerol and 0.03% Proclin 300 as preservative in 0.01M PBS at pH 7.4, which helps maintain stability during storage .

Aliquoting the antibody upon receipt into single-use volumes is recommended to prevent degradation from multiple freeze-thaw cycles, which can affect binding efficiency and increase background signal in experiments.

How should researchers validate YOR034C-A antibodies before experimental use?

Proper validation of YOR034C-A antibodies is essential for ensuring experimental reproducibility. Based on current standards for antibody validation, researchers should implement a multi-step approach:

• Knockout validation: Testing the antibody in wild-type versus YOR034C-A knockout yeast strains represents the gold standard for specificity validation. Recent research has demonstrated that knockout cell lines provide superior controls compared to other validation methods, particularly for Western blot and immunofluorescence applications .

• Molecular weight verification: Confirm that the detected band in Western blot appears at the expected molecular weight for the YOR034C-A protein.

• Positive and negative controls: Include samples known to express (positive control) or not express (negative control) the target protein.

• Cross-validation with orthogonal methods: Verify protein expression using independent techniques such as mass spectrometry or qPCR for mRNA levels .

Studies have shown that approximately 50% of commercial antibodies fail to meet basic standards for characterization, resulting in significant financial losses and irreproducible research . Therefore, thorough validation is critical before proceeding with experiments.

What controls are necessary when using YOR034C-A antibodies in Western blot applications?

When performing Western blot with YOR034C-A antibodies, the following controls should be implemented:

• Knockout or knockdown control: The most stringent control involves using a YOR034C-A gene knockout strain alongside wild-type samples. Recent research by YCharOS demonstrated that knockout controls are superior to other types of controls for Western blot applications .

• Loading control: Include antibodies against housekeeping proteins (e.g., actin, GAPDH) to ensure equal protein loading across lanes.

• Secondary antibody-only control: Include a lane where only secondary antibody is applied to identify potential non-specific binding.

• Positive control: Include a sample where YOR034C-A is known to be expressed, if available.

• Molecular weight marker: Always include a protein ladder to verify that the detected band appears at the expected molecular weight.

These controls help distinguish between specific and non-specific signals, ensuring that experimental observations are reliable and reproducible .

How can researchers address batch-to-batch variation issues with YOR034C-A antibodies?

Batch-to-batch variation is a significant challenge with biological reagents like antibodies. For YOR034C-A antibodies, researchers should implement the following strategies:

• Lot testing: Validate each new lot against a previously validated lot using the same experimental conditions and samples.

• Reference sample maintenance: Maintain a frozen stock of reference samples with known YOR034C-A expression levels to test each new antibody lot.

• Detailed record-keeping: Document antibody lot numbers, dilutions, and performance metrics in laboratory records and methods sections of publications.

• Consider recombinant alternatives: Evidence suggests that recombinant antibodies demonstrate greater consistency and on average outperform both monoclonal and polyclonal antibodies across multiple assays .

• Validation data comparison: Request and compare validation data from vendors for each batch to identify potential performance differences .

A recent study analyzed 614 antibodies targeting 65 proteins and found that vendors proactively removed approximately 20% of antibodies that failed to meet expectations, highlighting the importance of continuous validation .

What methodological approaches can enhance reproducibility when working with YOR034C-A antibodies?

To enhance experimental reproducibility with YOR034C-A antibodies, researchers should:

• Standardize protocols: Develop and strictly adhere to detailed protocols for sample preparation, antibody dilution, incubation times, washing steps, and detection methods.

• Titrate antibody concentrations: Determine the optimal working concentration for each application by testing a range of dilutions.

• Use appropriate blocking agents: Optimize blocking conditions to minimize background while preserving specific signal.

• Validate across applications: If using the antibody for multiple applications (WB, ELISA, etc.), validate specifically for each technique rather than assuming cross-application performance .

• Document completely: Record all experimental details, including antibody source, catalog number, lot number, dilution, and incubation conditions in both laboratory notebooks and publications .

• Share validation data: Contribute to community resources by sharing antibody validation data through repositories or supplementary materials in publications .

What are the best practices for reporting YOR034C-A antibody use in scientific publications?

Comprehensive reporting of antibody usage is essential for research reproducibility. Best practices include:

• Complete antibody identification: Report the antibody name, manufacturer, catalog number, lot number, RRID (Research Resource Identifier) if available, host species, clonality (polyclonal/monoclonal/recombinant), and immunogen used for generation .

• Validation evidence: Describe the validation experiments performed or cite relevant validation studies. For YOR034C-A antibody, include details of specificity testing in yeast strains.

• Protocol transparency: Provide detailed methodological information including dilutions, incubation conditions, buffers, and detection methods.

• Control experiments: Describe all controls used to interpret results, particularly knockout controls which have been shown to be superior for specificity validation .

• Raw data availability: Consider making unprocessed blot images or other raw data available through repositories or supplementary materials.

A shocking finding from recent research revealed that for some proteins, an average of ~12 publications included data from antibodies that failed to recognize their intended target protein, highlighting the critical importance of thorough reporting and validation .

How should researchers troubleshoot weak or absent signals when using YOR034C-A antibodies?

When faced with weak or absent signals when using YOR034C-A antibodies, consider the following troubleshooting approach:

• Protein expression verification: Confirm that YOR034C-A is expressed in your samples using alternative methods (e.g., qPCR for mRNA expression).

• Sample preparation optimization:

  • Ensure complete cell lysis

  • Add protease inhibitors to prevent protein degradation

  • Optimize protein extraction protocol for yeast cells, which have tough cell walls

• Antibody concentration adjustment: Increase antibody concentration incrementally, starting with a 2-fold increase from the recommended dilution.

• Incubation conditions modification:

  • Extend primary antibody incubation time (e.g., overnight at 4°C)

  • Test different incubation temperatures

• Detection system enhancement:

  • Use a more sensitive detection system

  • Increase exposure time for chemiluminescence detection

  • Consider signal amplification methods

• Cross-validation: Test a different antibody against the same target if available to determine if the issue is sample-related or antibody-specific .

What experimental design considerations are important when studying post-translational modifications of YOR034C-A?

When investigating potential post-translational modifications (PTMs) of YOR034C-A:

• Modification-specific antibodies: Consider whether modification-specific antibodies (phospho-specific, etc.) are available or could be developed.

• Sample preparation adjustments:

  • Include phosphatase inhibitors for phosphorylation studies

  • Add deubiquitinase inhibitors for ubiquitination studies

  • Use gentle lysis conditions to preserve native modifications

• Control treatments:

  • Include samples treated with enzymes that remove specific modifications (e.g., phosphatases)

  • Use inhibitors or activators of relevant modification pathways

• Resolution optimization:

  • Use Phos-tag or similar gels for phosphorylation studies

  • Consider 2D gel electrophoresis to separate modified forms

• Complementary techniques:

  • Verify PTMs using mass spectrometry

  • Use immunoprecipitation followed by PTM-specific Western blotting

• Functional validation: Design experiments to test the functional significance of identified modifications .

How can researchers contribute to improving YOR034C-A antibody characterization?

Researchers can contribute to improving YOR034C-A antibody characterization through several approaches:

• Participation in community initiatives: Join efforts like Only Good Antibodies (OGA) or YCharOS that work to improve antibody validation and characterization .

• Data sharing: Publish detailed validation data for YOR034C-A antibodies used in research, including both positive and negative results.

• Protocol standardization: Contribute to the development of standardized protocols for YOR034C-A antibody validation and use in different applications.

• Knockout resources: Generate and share YOR034C-A knockout yeast strains that can serve as validation tools for the research community.

• Cross-laboratory validation: Participate in multi-laboratory studies to assess antibody performance across different settings and applications.

• Grant planning: When writing grant applications for research requiring YOR034C-A antibodies, include specific aims and budget for antibody validation and characterization .

The Only Good Antibodies (OGA) community, established in 2023, aims to promote awareness of antibody issues, educate researchers, improve availability of characterization data, and enhance data sharing—all principles that can be applied to improving YOR034C-A antibody research .

What are the emerging alternatives to traditional antibody-based detection of YOR034C-A?

Several emerging technologies offer alternatives to traditional antibody-based detection:

• Recombinant antibody fragments: Single-chain variable fragments (scFvs) or nanobodies derived from YOR034C-A antibodies can provide more consistent performance. Recent studies have demonstrated that recombinant antibodies outperform both monoclonal and polyclonal antibodies across multiple assays .

• CRISPR-based tagging: Endogenous tagging of YOR034C-A with epitope tags (e.g., FLAG, HA) or fluorescent proteins using CRISPR-Cas9, allowing detection with well-characterized anti-tag antibodies.

• Proximity labeling approaches: BioID or APEX2 fusion proteins to identify proteins in proximity to YOR034C-A without direct antibody detection.

• Mass spectrometry-based proteomics: Label-free or isotope-labeled quantitative proteomics to measure YOR034C-A levels and modifications.

• Aptamer development: DNA or RNA aptamers specifically selected against YOR034C-A protein as antibody alternatives.

• Computational prediction: Using machine learning algorithms to predict protein expression patterns based on genomic and transcriptomic data .

Each of these alternatives offers distinct advantages and limitations, and researchers should select the approach most appropriate for their specific research question and experimental system.